End-stage renal disease after treatment with 90 Y-DOTATOC

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

Andreas Otte, E. Jermann, Martin Béhé et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1997 · 214 citations

Medicine, Molecular Pharmaceutics, Nuclear Medicine +14

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

Giovanni Paganelli, Stefania Zoboli, Marta Cremonesi et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 205 citations

Medicine, Oncology, Radiation Oncology +12

RADIATION NEPHRITIS

R.W. Luxton · The Lancet · 1961 · 113 citations

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.

Adrian Merlo, Oliver Hausmann, M. Wasner et al. · PubMed · 1999 · 96 citations

Medicine, Oncology, Pharmacology +17

Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy

Johnathan Cohen · International Journal of Radiation Biology · 1998 · 47 citations

Medicine, Pharmacology, Pharmacotherapy +10